Perioperative immune checkpoint inhibitors with chemotherapy increase pathological complete response rate by 2.91 RR
Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Cancer Response
This meta-analysis of randomized controlled trials evaluated perioperative immune checkpoint inhibitors combined with chemotherapy for resec…
Adding immune checkpoint inhibitors to chemotherapy may significantly improve response rates for patients with certain types of stomach and …
Zolbetuximab combined with chemotherapy improves progression-free survival and overall survival in CLDN18.2-expressing gastric cancers
New drug shows promise for advanced stomach and esophageal cancer
This systematic review evaluates zolbetuximab in combination with chemotherapy for patients with advanced G/GEJ adenocarcinoma expressing hi…
A new treatment called zolbetuximab may improve survival rates for patients with specific types of advanced stomach and esophageal cancers.